Table I.
Patient characteristics categorized by warfarin use
| Parameter | All patients (n = 1453) |
On-warfarin (n = 647) |
Non-warfarin (n = 806) |
P-value |
|---|---|---|---|---|
| Female | 649 (44.7) | 301 (46.5) | 348 (43.2) | 0.203 |
| Age [years]: | ||||
| Mean ± SD | 69.1 ±11.2 | 67.7 ±10.8 | 70.2 ±11.4 | < 0.001 |
| < 40 | 17 (1.2) | 9 (52.9) | 8 (47.1) | < 0.001 |
| 40–64 | 428 (29.5) | 213 (49.8) | 215 (50.2) | |
| 65–74 | 474 (32.6) | 229 (48.3) | 245 (51.7) | |
| ≥ 75 | 534 (36.8) | 196 (36.7) | 338 (63.3) | |
| Blood pressure on admission, n = 1443* (641 on-warfarin), mean ± SD [mm Hg] | ||||
| SBP | 129.9 ±21.0 | 129.9 ±20.5 | 130.0 ±21.4 | 0.897 |
| DBP | 77.7 ±12.6 | 78.1 ±12.1 | 77.5 ±13.0 | 0.373 |
| LVEF, n = 1261* (575 on-warfarin): | ||||
| Mean ± SD | 57.8 ±12.1 | 57.9 ±12.2 | 57.8 ±12.1 | 0.916 |
| < 55% | 416 (33.0) | 192 (46.2) | 224 (53.8) | 0.810 |
| ≥ 55% | 845 (67.0) | 383 (45.3) | 462 (54.7) | |
| Type of atrial fibrillation: | ||||
| Paroxysmal | 316 (21.7) | 133 (42.1) | 183 (57.9) | 0.338 |
| Persistent/Permanent | 1137 (78.3) | 514 (45.2) | 623 (54.8) | |
| CHA2DS2-VASc score: | ||||
| Median (IQR) | 3 (2–4) | 3 (2–4) | 3 (2–4) | 0.942 |
| Male = 0 or female = 1 | 138 (9.5) | 78 (43.5) | 60 (56.5) | 0.777 |
| Male = 1 or female = 2 | 257 (17.7) | 110 (42.8) | 147 (57.2) | |
| Male ≥ 2 or female ≥ 3 | 1058 (72.8) | 477 (45.1) | 581 (54.9) | |
CHA2DS2-VASc – congestive heart failure, hypertension, age ≥ 75 years (double), diabetes mellitus, stroke/transient ischemic stroke/thromboembolism history (double), vascular disease, age (65–74), sex (female), DBP – diastolic blood pressure, IQR – interquartile range, LVEF – left ventricular ejection fraction, SBP – systolic blood pressure, SD – standard deviation; *the number of patients with available data.